CNSP icon

CNS Pharmaceuticals
CNSP

12 hedge funds and large institutions have $349K invested in CNS Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

more ownership

Funds ownership: →

less capital invested

Capital invested by funds: $ → $
Holders
12
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$96.1K
2
+$50.4K
3
+$5.43K
4
UBS Group
UBS Group
Switzerland
+$489
5
CIAM
Caitong International Asset Management
Hong Kong
+$4

Top Sellers

1
-$81K
2
-$21
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$146K
IC
2
Ikarian Capital
Texas
$110K
Geode Capital Management
3
Geode Capital Management
Massachusetts
$55.7K
BFM
4
Boothbay Fund Management
New York
$32.3K
TRCT
5
Tower Research Capital (TRC)
New York
$3.13K
UBS Group
6
UBS Group
Switzerland
$1.74K
SIS
7
Sound Income Strategies
Florida
$36
BC
8
Barrett & Company
Rhode Island
$19
MCM
9
MAI Capital Management
Ohio
$8
DB
10
Danske Bank
Denmark
$2
CIAM
11
Caitong International Asset Management
Hong Kong
$2
Citigroup
12
Citigroup
New York
$2
DS
13
DRW Securities
Illinois
–
Bank of America
14
Bank of America
North Carolina
–